Alternative pre-mRNA splicing occurs extensively in the nervous systems of complex organisms, including humans, considerably expanding the potential size of the proteome. Cell-specific alternative pre-mRNA splicing is thought to optimize protein function for specialized cellular tasks, but direct evidence for this is limited. Transmission of noxious thermal stimuli relies on the activity of N-type Ca V 2.2 calcium channels in nociceptors. Using an exon-replacement strategy in mice, we show that mutually exclusive splicing patterns in the Ca V 2.2 gene modulate N-type channel function in nociceptors, leading to a change in morphine analgesia. Exon 37a (e37a) enhances m-opioid receptor-mediated inhibition of N-type calcium channels by promoting activity-independent inhibition. In the absence of e37a, spinal morphine analgesia is weakened in vivo but the basal response to noxious thermal stimuli is not altered. Our data suggest that highly specialized, discrete cellular responsiveness in vivo can be attributed to alternative splicing events regulated at the level of individual neurons.
a r t I C l e S Alternative pre-mRNA splicing is used extensively in the nervous systems of complex organisms, including humans [1] [2] [3] . Transcriptome analyses suggest that alternative pre-mRNA splicing events occur in the vast majority of multi-exon human genes 4 . Furthermore, an increasing number of human diseases are linked to defects in alternative splicing 5 . Neurons are thought to use alternative splicing to add and subtract discrete protein modules encoded by alternative exons, optimizing protein function for specific cellular tasks. There is evidence that cell-dependent inclusions of alternatively spliced exons in ion channels and receptors act like molecular switches, permitting new interactions that control channel gating and receptor targeting 1, 6, 7 . However, there are few studies linking a specific splicing event in an identified population of neurons to changes in native protein function and behavior 1, 2 . The challenge is perhaps greatest in the nervous system, where a heterogeneous population of neurons express a vast number of multi-exon genes 2, 8 . Here we study the function of one site of alternative splicing in the Cacna1b gene, which encodes the pore-forming subunit of the N-type channel.
Ion channels underlie all electrical signals in the nervous system 9 . They are highly sensitive to perturbations in their structure or chemical environment. Moreover, these changes can be monitored with precision. Studies of ion-channel splice isoforms have shown that alternatively spliced exons in ion channels can modify plasma membrane and subcellular targeting and trafficking, second-messenger sensitivities and channel gating properties 1, 6, 10 .
Alternatively spliced exons in genes encoding voltage-gated calcium channels have been shown to have tissue-specific expression patterns and to modify channel activity and drug sensitivity 1, 7, [11] [12] [13] [14] [15] . But there is little data on the cellular consequences in neurons and none on the behavioral consequences of regulated alternative splicing events. We have focused on Cacna1b, the gene encoding the presynaptic calcium channel Ca V 2.2, which is the core of the N-type calcium channel. In particular, we focus on a pair of mutually exclusive exons in Ca V 2.2 mRNA, e37a and e37b, which encode 32 amino acid residues in the proximal region of the protein's C terminus. Fourteen of the 32 residues differ between e37a and e37b. E37a has an intriguing expression profile: Ca V 2.2[e37a] mRNAs are enriched in nociceptors of dorsal root ganglia (DRG) and expressed at lower levels in other regions, including brain, while Ca V 2.2[e37b] mRNAs are ubiquitous in the nervous system 16, 17 . By studying clones of Ca V 2.2 splice isoforms expressed in a mammalian cell line, we have previously shown that e37a creates an inhibitory domain in the Ca V 2.2 protein that renders N-type calcium channels sensitive to a form of G i/o proteindependent inhibition that persists when cells are depolarized 7 . We have also found that e37a promotes greater N-type current density 16, 17 . In vivo silencing of Ca V 2.2[e37a] reduces basal thermal nociception, suggesting this isoform participates in transmission at C-fiber terminals 18 . But the role of Ca V 2.2[e37a] channels in G i/o protein inhibition of native N-type channels in the pain pathway remains unexplored.
With this in mind, we devised a mouse model to determine why Ca V 2.2[e37a] channels are enriched in nociceptors of DRG. We eliminated e37a from the mouse Cacna1b gene and replaced it with a second 37b-encoding exon. By comparing these mice to wild-type mice that express both e37a and e37b isoforms, we show that e37a regulates μ-opioid receptor-mediated inhibition of native N-type calcium channels in nociceptors and that spinal-level analgesia by morphine in vivo is reduced in the absence of e37a by a mechanism that does not affect basal transmission of noxious thermal stimuli.
RESULTS

Exon substitution in the Cacna1b mouse gene
To determine how e37a affects N-type calcium channel activity in vivo, we chose an exon-substitution strategy aimed at eliminating a r t I C l e S the Ca V 2.2[e37a] splice isoform while preserving cell-directed splicing and N-type channel expression. Figure 1 illustrates our approach. E37a and e37b are mutually exclusive and identical in size, and can substitute for each other structurally and, in part, functionally. We replaced e37a in the mouse Cacna1b gene with an e37b sequence (e37b*), creating tandem 37b exons (Cacna1b b*b/b*b ) and eliminating e37a; we also generated mice expressing e37a only (Cacna1b aa*/aa* ) by the same strategy, replacing e37b in Cacna1b with e37a sequence (e37a*) ( Fig. 1 and Supplementary Fig. 1 ). Correct Cacna1b targeting was verified by genomic PCR (Supplementary Fig. 1 ) and sequencing. Mice homozygous for each mutation, Cacna1b b*b/b*b and Cacna1b aa*/aa* , were viable and fecund. Cacna1b b*b/b*b homozygotes were born at wild-type frequencies, but Cacna1b aa*/aa* homozygotes were born at ~50% of the expected Mendelian rate ( Supplementary Table 1 ). Our data suggest that Cacna1b b*b/b*b homozygotes tolerate e37b* as a replacement exon for e37a, whereas Cacna1b aa*/aa* homozygotes are physiologically compromised. These results point to a global disruption of N-type calcium channel function ( Supplementary Table 1 ).
To distinguish mutant (e37a* and e37b*) from wild-type expressed sequences (e37a and e37b) we introduced synonymous point mutations. We eliminated the BsrGI restriction site in e37a and the XhoI restriction site in e37b. A combination of reverse-transcription PCR (RT-PCR) and restriction digest analysis showed that e37b*-and e37a*-containing mRNAs were expressed in DRG of mutant mice (Fig. 1b,c and Supplementary Fig. 1 ).
Alternative splicing patterns were comparable for Cacna1b b*b/b*b and wild-type mice in DRG. Although not quantitative, our PCR analyses suggest that the proportion of e37b* in mutants was similar to that of e37a in wild-type DRG (Fig. 1c) . Similarly, the proportion of e37b-derived RT-PCR products amplified in mutants was comparable to that of e37b-derived products in wild-type DRG (Fig. 1c) . These results, combined with our previous studies in rat, suggest that e37a-containing mRNAs are enriched in DRG relative to other parts of the nervous system but Ca V 2.2[e37b] mRNAs still represent the most common Ca V 2.2 isoform in RNA of whole DRG 16, 17 .
In contrast, expression patterns of Ca V 2.2[e37a] and Ca V 2.2[e37a*] mRNAs in DRG of Cacna1b aa*/aa* mice are different from those in wild-type mice (Fig. 1c) . First, from Cacna1b aa*/aa* DRG we amplified a PCR product of 335 base pairs (bp) that was resistant to both XhoI and BsrGI cleavage ( Fig. 1c) . DNA sequence analysis showed this cDNA product was amplified from Ca V 2.2 mRNAs that lacked exon 37 (Δ37; Fig. 1b ). We know from our previous analyses that Ca V 2.2 mRNAs lacking both e37a and e37b create a shift in the reading frame, an early stop codon, and nonfunctional Ca V 2.2 protein 19 . Second, the relative abundances of e37a-and e37a*-containing Ca V 2.2 mRNAs in DRG of Cacna1b aa*/aa* mice are different from those of Ca V 2.2[e37a] and Ca V 2.2[e37b] mRNAs in wild-type mice ( Fig. 1c) . Below we show that N-type currents and Ca V 2.2 protein levels in DRG of Cacna1b aa*/aa* mice are also substantially reduced relative to wild-type mice.
Ca 2+ currents in DRG of Cacna1b b*b/b*b and wild-type mice
We have previously reported that Ca V 2.2[e37a] mRNAs are enriched in DRG, specifically in small-diameter nociceptors defined by their capsaicin sensitivity 16 . We have also shown in a mammalian expression system that e37a promotes voltage-independent inhibition of N-type currents through μ-opioid receptor activation 7 . To test the role of e37a in mediating inhibition of native N-type current in capsaicinresponsive small-diameter neurons of DRG, we first distinguished these neurons from two other classes of neurons (large and T-rich). We did this by assessing capsaicin sensitivity, cell capacitance (size) and calcium channel properties ( Supplementary Fig. 2) .
Small neurons had small membrane capacitances tightly distributed around an average value of 13 pF. These were readily separable from large neurons (37 pF; Supplementary Fig. 2) . We found the vast majority of small neurons were capsaicin responsive (17 of 21; Supplementary Fig. 2) , whereas large neurons rarely responded to capsaicin (1 of 19; Supplementary Fig. 2) . A third group of neurons (T-rich 20 ) expressed large T-type calcium currents that characteristically activate at low voltages and deactivate with slow kinetics (Fig. 2) . and treated with BsrGI (lanes 2, 5 and 8) or XhoI (lanes 3, 6 and 9) were separated on a 2% TAE agarose gel. Lanes 1-9 are flanked by 1 kb Plus DNA ladders. A 335-bp product was amplified from DRG of aa* mice and was resistant to BsrGI and XhoI. Sequencing showed that it corresponds to mRNA lacking e37 (Δ37). a r t I C l e S These were intermediate in size and did not respond to capsaicin, but by virtue of their large T-type currents they were easily identified and separated from small and large neurons ( Supplementary Fig. 2 ).
Whole-cell calcium currents in all three groups of DRG neurons from Cacna1b b*b/b*b mice were indistinguishable from those in wild type mice (Cacna1b ab/ab ; Fig. 2a-c) . DRG neurons express at least four different classes of calcium channels, N-type, P/Q-type, L-type and T-type; N-type represents the largest component 16, 20, 21 . We isolated pure N-type from non-N-type currents using the N-type calcium channel blocker 2 μM ω-conotoxin GVIA and found that N-type currents in DRG neurons of Cacna1b b*b/b*b mice were also indistinguishable from the wild type ( Fig. 3) . These data support our RT-PCR analyses that show e37b* can substitute for e37a and support wild-type splicing patterns in DRG neurons.
N-type Ca 2+ currents in aa* mice are smaller than in wild type In contrast to Cacna1b b*b/b*b , N-type currents in small and large neurons of Cacna1b aa*/aa* mice were significantly smaller than in wild-type mice (Student's t-test, P = 0.000238; Fig. 3a) . In addition, T-type currents in T-rich neurons were slightly larger than in wild-type mice, but the difference was not statistically significant (Student's t-test, P = 0.245; Figs. 2 and 3) . Ca V 2.2 protein levels in DRG ( Fig. 2d ) and in brains ( Supplementary Fig. 3 ) of Cacna1b aa*/aa* mice were reduced relative to wild-type mice. This reduction was specific to Ca V 2.2 protein and did not lead to compensatory changes in levels of the closely related Ca V 2.1 protein in brains of Cacna1b aa*/aa* mice. The reduction in Ca V 2.2 protein levels in DRG of Cacna1b aa*/aa* mice could not be explained by differences in cell size; whole-cell capacitance values within (a-f) Average N-type (a-c) and non-N-type (d-f) calcium current-voltage relationships in three subtypes (small, large and T-rich) of acutely dissociated DRG neurons from wild-type,
and Cacna1b aa*/aa* (aa*) mice. Representative currents shown above current voltage plots were evoked by test pulses to 0 mV from a holding potential of −80 mV and were recorded from each cell type and each mouse line. Currents were elicited as described in Figure 2 and plotted as pA/pF to normalize for cell size. N-type currents and non-N-type currents correspond to ω-conotoxin GVIA-sensitive and ω-conotoxin GVIA-insensitive components of the whole-cell current, respectively. We isolated N-type currents in each cell by subtracting non-N-type currents (insensitive to 2 μM ω-conotoxin GVIA) from whole-cell currents. N-type current densities in small (a) and large (b) neurons were significantly smaller in Cacna1b aa*/aa* mice than in wild-type mice (P = 0.0003 and P = 0.0038, respectively). Individual current voltage plots were fit with one (a-e) or two (f) Boltzmann functions using average parameters calculated from fitting individual curves (Supplementary Table 2 ). Scale bars, 500 pA and 5 ms. Data are means ± s.e.m. n values in parentheses are number of cells; all data sets contain recordings from at least nine mice. Currents were evoked by test pulses to −30 mV (left) and 0 mV (right) from a holding potential of −80 mV. A series of currents were elicited by depolarizations applied every 10 s to test potentials between −70 mV and +80 mV from a holding potential of −80 mV. Current densities are plotted (pA/pF) for small cells (a, 13pF), large cells (b, 35pF) and T-rich cells (c, 24pF). Calcium current densities of small (a) and large (b) neurons from Cacna1b aa*/aa* mice were significantly smaller than those from wild-type mice (P = 0.0004 and P = 0.03, respectively). Individual current voltage plots were fit with one (a,b) or two (c) Boltzmann functions using average parameters calculated from fitting individual curves (Supplementary Table 2 ). Scale bars, 500 pA and 5 ms. Data are means ± s.e.m. n values shown in parentheses are number of cells; all data sets contain recordings from at least nine mice. (d) Western blot of DRG lysates derived from wild-type, aa* and b*b mice using a polyclonal antibody directed to Ca V 2.2 and a monoclonal antibody directed to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Ca V 2.2 protein levels in DRG of aa* mice were lower than in wild-type mice. Ca V 2.2 protein runs at 260 kDa; location of a 250-kDa size marker is indicated. Complete, uncropped blots are shown in Supplementary Figure 5 .
a r t I C l e S each subset of neurons were indistinguishable among genotypes ( Supplementary Fig. 2 ). Furthermore, we compared calcium current densities (pA pF −1 ) to normalize for cell size (Figs. 2  and 3) . N-type currents in all three groups of DRG neurons from Cacna1b aa*/aa* mice activated at voltages ~7 mV more hyperpolarized than the voltages at which N-type currents were activated in neurons of wild-type and Cacna1b b*b/b*b mice ( Fig. 3a-c) . Our findings are highly consistent with our previous studies of cloned e37a-containing N-type channels expressed in mammalian and amphibian cells. These similarly activated at voltages ~7 mV more hyperpolarized than e37b-containing N-type channels 7, 16, 17 .
The reduction of Ca V 2.2 protein levels in Cacna1b aa*/aa* mice probably results from a disruption in alternative splicing, consistent with the data from e37a-lacking Ca V 2.2 mRNAs in DRG ( Fig. 1c) . We next compared G protein inhibition of N-type currents in small-diameter nociceptors from our various mouse lines, but with our primary focus on Cacna1b b*b/b*b and wild-type recordings, because Ca V 2.2 protein levels are reduced in Cacna1b aa*/aa* mice.
DAMGO inhibits Ca 2+ currents in all genotypes similarly
In previous studies of cloned Ca V 2.2[e37a] and Ca V 2.2[e37b] channels in a mammalian cell line, we have shown that e37a-containing N-type channels promote voltage-independent inhibition of N-type currents via G protein-coupled receptors without affecting overall inhibition of peak current 7 . We next tested whether e37a regulates the responsiveness of native N-type currents to μ-opioid receptor-mediated inhibition in nociceptors that express both Ca V 2.2[e37a] and Ca V 2.2[e37b] mRNAs under normal circumstances 16 .
We used a saturating concentration of the opioid peptide DAMGO (10 μM) to activate μ-opioid receptors and monitored the effects on N-type and non-N-type currents in nociceptors of Cacna1b b*b/b*b and wild-type mice (Fig. 4) . Overall, we found DAMGO was a more effective inhibitor of N-type (70-75%) than of non-N-type (15-25%) current, as reported elsewhere 21 . DAMGO inhibited N-type current amplitudes in nociceptors from Cacna1b b*b/b*b and wild-type mice equally (P = 0.64; Fig. 4f) . Similarly, the efficacy of DAMGO on N-type currents in small neurons of Cacna1b aa*/aa* mice was not significantly different from its efficacy in wild-type mice (P = 0.49; Fig. 4f ).
E37a promotes voltage-independent inhibition by DAMGO
If e37a does not influence the overall inhibitory action of DAMGO, does it affect the type of inhibition? To answer this question, we next tested whether e37a was important for voltage-independent inhibition of N-type currents by DAMGO.
We used standard strong, brief, suprathreshold depolarizations to 80 mV just before the test pulse to remove voltage-dependent inhibition mediated by saturating concentrations of DAMGO ( Fig. 5) . This allowed us to calculate the relative amounts of voltage-dependent and voltage-independent inhibition of non-N-type and N-type currents (Fig. 5g,h) . DAMGO inhibited non-N-type currents by voltagedependent and voltage-independent mechanisms, and the relative contribution of each was the same in neurons of wild-type, Cacna1b b*b/b*b and Cacna1b aa*/aa* mice (70% voltage-independent; Fig. 5d-f,h) .
However, we observed substantial differences when we compared DAMGO's effects on N-type currents in nociceptors of Cacna1b b*b/b*b mice compared with wild-type mice (P = 0.032; Fig. 5g ). Even though peak N-type currents in nociceptors of all three genotypes were inhibited equally well by DAMGO ( Fig. 4) , its inhibitory effects were mostly voltage-dependent in neurons of Cacna1b b*b/b*b mice (75% voltagedependent; Fig. 5b,g) , in contrast to wild-type mice (50% voltagedependent; Fig. 5a,g) . In other words, DAMGO caused significantly less voltage-independent inhibition of N-type currents in nociceptors of Cacna1b b*b/b*b mice. It was only in nociceptors of Cacna1b b*b/b*b mice that we observed a shift from voltage-independent toward voltage-dependent inhibition of N-type currents; DAMGO's effects on N-type currents in nociceptors of Cacna1b aa*/aa* mice (Fig. 5c,g) and on non-N-type currents in Cacna1b b*b/b*b and Cacna1b aa*/aa* mice (Fig. 5e,f,h) were the same as in wild-type mice. This is generally consistent with our studies of cloned Ca V 2.2[e37a] and Ca V 2.2[e37b] channels expressed in tsA201 cells 7 .
E37a influences spinal-level analgesia by morphine
Our electrophysiological analyses show that e37a promotes a form of N-type channel inhibition in nociceptors that is resistant to depolarization (voltage-independent). We also compared the overall distribution of Ca V 2.2 protein in the dorsal spinal horn of wild-type, Cacna1b b*b/b*b and Cacna1b aa*/aa* mice by immunohistochemistry. a r t I C l e S The overall pattern of anti-Ca V 2.2 signal was similar among the three genotypes, as were gross patterns of anti-CGRP signal and IB4 fluorescence. Although not quantitative, these signals suggest there are no gross disruptions of Ca V 2.2 distribution in afferent terminals in the superficial laminae of the dorsal spinal horn where afferents of nociceptors terminate (Fig. 6) .
We next used our mouse models to test the role of e37a in (i) basal nociception and (ii) spinal analgesia by morphine. Small capsaicin-responsive nociceptors transmit information about noxious thermal stimuli. Intrathecal morphine, acting through μ-opioid receptors, inhibits transmission in this pathway 22, 23 . At least part of morphine's spinal-level analgesia is through μ-opioid receptor-mediated inhibition of presynaptic N-type channels on nociceptor terminals in the dorsal horn of the spinal cord 24, 25 . To assess this pathway, we applied standard thermal stimuli to the hind paw and measured paw-withdrawal latencies in all three mouse lines. This behavioral test specifically assesses spinal-level circuits 26, 27 . Paw-withdrawal latencies measured from wild-type, Cacna1b b*b/b*b and Cacna1b aa*/aa* mice were the same (Fig. 7a) . Our data suggest that amino acid residues unique to e37a are not necessary for normal transmission of noxious thermal stimuli.
Finally, we tested whether e37a contributes to the analgesic actions of intrathecal morphine. This route of administration restricts the site of morphine action to the spinal cord and rules out contributions from supraspinal sites 28, 29 . At doses higher than 3 μg, morphine induced behavior that interfered with testing. At its peak, 3 μg morphine induced analgesia to a level 70% of the maximum possible effect against the thermal stimulus, similar to other reported results 30 . We found substantial differences in the analgesic efficacy of intrathecal morphine in Cacna1b b*b/b*b mice compared with wild-type mice a r t I C l e S ( Fig. 7b-d) . As reported 29 , intrathecal morphine transiently lengthened latencies of paw withdrawal in response to thermal stimuli. Overall, morphine was 30% less effective as an analgesic at 3 μg in Cacna1b b*b/b*b than in wild-type mice (n = 20, Student's two-tailed t-test, P = 0.004; Fig. 7b ). By comparison, morphine was similarly effective at prolonging paw-withdrawal latencies in Cacna1b aa*/aa* and wild-type mice (n = 14, P = 0.77; Fig. 7b) . We compared the time courses of morphine-induced analgesia in Cacna1b b*b/b*b , Cacna1b aa*/aa* and wild-type mice (Fig. 7c,d) . The analgesic effect of 3 μg morphine was apparent within 10 min and peaked at 20-30 min; the effect was reduced in Cacna1b b*b/b*b mice at all time points tested. These differences are significant at 20, 30, 50 and 60 min (Student's two-tailed t-test, P = 0.008-0.044; Fig. 7c ).
Finally, we compared the efficacy of two lower doses of intrathecal morphine in wild-type and Cacna1b b*b/b*b mice. Although there is no significant difference between wild-type and Cacna1b b*b/b*b mice in the overall efficacy of morphine at 0.1 μg and 0.3 μg (P = 0.69 and P = 0.75, respectively; Supplementary Fig. 4) , the dose-response relationships are significantly different, as indicated by their slopes (Student's t-test, P = 0.04; Supplementary Fig. 4) . Our data suggest that e37a is needed for the maximal spinal-level analgesic actions of morphine at higher doses, in response to noxious thermal stimuli.
DISCUSSION
Cell-directed alternative pre-mRNA splicing is thought to represent an important step in optimizing protein function for specialized tasks, but few if any studies have linked a single splicing event to a specific behavior in mammals 1, 2 . We used an exon-replacement strategy to show that it is possible to attribute a decrease in the efficacy of morphine to a single RNA processing event. We suggest that cell-specific selection of e37a during alternative pre-mRNA splicing enhances activity-independent G protein inhibition of N-type calcium channels in nociceptors. The enrichment of e37a in nociceptors may augment the analgesic actions of morphine in vivo.
Intrathecal morphine may need e37a for maximal efficacy Our approach took advantage of a localized splicing event in a well-described population of functionally specialized neurons, which underlie a behavior that can be measured reliably. Capsaicinresponsive small-diameter nociceptors of unmyelinated C-fibers are specialized to transmit noxious thermal stimuli 22, 31 . N-type Ca V 2.2 calcium channels at presynaptic terminals of C-fiber afferents in the spinal cord mediate transmitter release and behavioral responses to noxious stimuli 32 . Morphine occludes transmission of noxious thermal stimuli in the spinal cord in large part by μ-opioid receptormediated inhibition of presynaptic N-type channels at nociceptor terminals [32] [33] [34] [35] [36] . By comparing behavioral responses in Cacna1b b*b/b*b and wild-type mice, we have obtained evidence that maximal analgesic actions of intrathecal morphine may depend on e37a-containing Ca V 2.2 channels (Fig. 7) . Collectively, our studies support the hypothesis that e37a boosts the analgesic effects of morphine via its influence on μ-opioid receptor-mediated inhibition of N-type calcium channels. E37a selectively augments voltage-independent inhibition of N-type currents without affecting the overall level of current inhibition (Figs. 4, 5 and 7) . Our conclusions about the role of e37a from the present studies on native channels and receptors are reinforced by our previous studies of cloned Ca V 2.2 isoforms and receptors expressed in the tsA201 cell line 7 .
Our analyses of Cacna1b b*b/b*b and wild-type mice suggest that, at higher doses, about 30% of morphine's analgesic actions at the level of the spinal cord rely on e37a-dependent inhibition of N-type channels. E37a-independent actions of morphine probably include voltage-dependent and voltage-independent inhibition of N-type calcium channels, and postsynaptic GIRK potassium channel activation via μ-opioid receptors 30 . Notably, the GIRK-dependent component of spinal analgesia by morphine is similar in magnitude and is engaged at the same concentration of morphine as we report for e37a 30 .
Paw-withdrawal latencies to noxious thermal stimuli were indistinguishable among genotypes, suggesting that Ca V 2.2[e37a] and Ca V 2.2[e37b] channels support transmission of nociceptive information in the spinal cord equally well. By contrast, studies using isoform-specific small interfering RNA suggest that Ca V 2.2[e37a] channels have a preferred role in transmission of noxious thermal stimuli 18 , in apparent contradiction to our analyses of Cacna1b b*b/b*b mice. However, these two observations might be reconcilable if Ca V 2.2[e37a] channels localize preferentially at transmitter release sites in nerve terminals of nociceptors of wild-type mice and in their absence (Cacna1b b*b/b*b ), Ca V 2.2[e37b] channels target to these presynaptic locations and support transmission of nociception with similar efficacy. There are no gross differences in anti-Ca V 2.2 signals in dorsal spinal horn among genotypes (Supplementary Fig. 4) , but experiments designed to quantify the density of presynaptic N-type channels would be needed to test these and other possibilities.
Cacna1b aa*/aa* mice are physiologically compromised, but our behavioral analyses suggest that transmission of nociceptive signals and morphine's analgesic actions are very similar to those in wild-type mice. This might be unexpected, because N-type currents a r t I C l e S and Ca V 2.2 protein levels are reduced in DRG neurons, but the results are consistent with reports that withdrawal latencies to thermal stimuli are unchanged in Cacna1b −/− null mice compared with wild-type mice 33, 37 . As noted above, experiments are needed to measure the relative contribution of N-type currents to transmission in the dorsal spinal horn.
Voltage-independent inhibition and morphine analgesia
Voltage-independent inhibition of N-type calcium currents has been studied for more than a decade [38] [39] [40] [41] [42] [43] . From these and other findings, a hypothesis has developed that voltage-independent inhibition of presynaptic N-type calcium channels via G protein-coupled receptors represents a mechanism for transmitter-and drug-mediated inhibition of synaptic transmission independent of neuronal activity 33, 40, 41, 43, 44 . By contrast, a purely voltage-dependent mechanism would inhibit N-type channels and synaptic transmission most strongly during periods of low neuronal activity, but would become less effective as activity increased 40, 44, 45 . Voltage-independent inhibition of N-type calcium channels through G i/o coupled receptors and e37a might underlie some of the analgesic actions of morphine, particularly at higher doses. However, e37a may also influence other properties of N-type channels, including cellular distribution and, as we report here, N-type current densities. One or all of these could influence the spinal-level actions of morphine.
Although morphine is a highly effective analgesic in response to noxious thermal stimuli in naïve mice and humans, it is much less effective against the thermal hyperalgesia characteristic of neuropathic pain 31 . Expression levels of many genes are altered in the DRG of animals experiencing neuropathic pain. These changes have been implicated in the development and maintenance of chronic pain as well as in the loss of morphine efficacy 31 . Ca V 2.2 mRNA and protein levels are not thought to change in DRG after peripheral nerve injury, but as we have reported 18 , Ca V 2.2[e37a] mRNAs are reduced. In light of the present study, it is possible that an injury-induced shift from e37a-containing to e37b-containing Ca V 2.2 channels in nociceptors, and therefore a concomitant change in inhibition of N-type calcium channels via μ-opioid receptors, might contribute to decreased spinallevel analgesia in response to morphine.
Cell-directed splicing of e37a
E37a is enriched in a subset of nociceptors in DRG 16 . What are the factors that control exon selection-an important step in the pain pathway-in these cells? Genome-wide analyses show that several proteins are involved in driving neuronal-specific alternative splicing 46, 47 , but there are few examples of how these factors coordinate exon selection in specific gene families within defined populations of neurons. Several neuronal splicing factors can function both as repressors and enhancers, depending on binding location with respect to the target exon, and exon selection probably depends on the relative contributions of several splicing factors working in concert 2, 47, 48 . The expression profile of e37a and the marked decrease in Ca V 2.2 protein levels in Cacna1b aa*/aa* mice suggest that most neurons may contain repressor activity that prevents e37a inclusion during splicing. However, our analysis of N-type current densities among small, T-rich and large cells of DRG from Cacna1b aa*/aa* mice suggest that e37a selection depends on additional factors with differential actions in these three classes of neuron. We studied Cacna1b gene sequences at and close to e37a and e37b splice junctions, but we have not identified the cis and trans factors that regulate alternative splicing at this site. We hope new data from genome-wide screens of splicing factor-RNA binding events will help define cell-specific mechanisms that orchestrate alternative splicing in Ca V 2 pre-mRNAs in specific neurons [46] [47] [48] .
The e37a/e37b splice site is conserved in all mammalian Cacna1b genes, so activity unique to e37a must provide some evolutionary advantage. Our data suggest that at higher doses morphine engages e37a in spinal analgesia to thermal stimuli, but it is likely that endogenous transmitters use this inhibitory pathway to control nociception under certain conditions. Identifying cell-specific splicing factors that control alternative splicing of e37a could lead to new therapeutic approaches to increase the efficacy of drugs and neurotransmitters that work through G protein-coupled receptors to inhibit N-type calcium channels. Such studies could also provide insight into cell-specific, coordinated alternative splicing of several pre-mRNAs that contribute to setting the efficacy of transmission in the pain pathway.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
ONLINE METhODS
construction of genomic clones for mouse exon substitution. To create Cacna1b b*b/b*b mice, we substituted e37a with e37b*; to create Cacna1b aa*/aa mice, we substituted e37b with e37a*. We derived mouse genomic DNA for all constructs from the MICER clone MHPN59f07 (Wellcome Trust Sanger Institute). Details of the cloning steps are given in Supplementary methods. To facilitate detection of the specific exons spliced into the final mRNA products, we introduced silent mutations into restriction sites of the substituted exons; we mutated the BsrGI site in the mutant e37a to produce e37a* and mutated the XhoI site in e37b to produce e37b*.
We inserted a 2-kilobase (kb) loxP-Neo R -loxP cassette into each targeting construct at the AfeI site located in the intron between the normal positions of e37a and e37b. We added flanking AfeI sites to the loxP-Neo R -loxP cassette amplified from PL452 by PCR with primers SD29for and SD31rev. Finally, we reintroduced the mutagenized DNA into BamHI-EagI sites to create the final ~12-kb targeting constructs in pBSSK+. mouse embryonic stem cell gene targeting and mouse breeding. Animal housing and experimental procedures were in accordance with Brown institutional animal care and use committee guidelines. In brief, we used 129Ola embryonic stem cells derived from a male embryo, grown on mitotically inactive SNL76/7 feeder cells. We transformed 10 7 embryonic stem cells with 20 μg of a construct linearized with PvuI and selected with G418 after 24 h. We selected 200 G418-resistant clones for further analysis. We used PCR to identify correctly targeted embryonic stem cell clones. We isolated E3.5 blastocysts from C57BL/6-Tyr c-Brd female mice and injected them with 12-20 embryonic stem cells harvested by trypsinization from 90%-confluence cultures. We then implanted injected blastocysts into day-2.5 pseudopregnant females to generate chimeras (eight to ten injected embryos per uterine horn). We mated male chimeras with C57BL/6-Tyr c-Brd females to obtain F1 progeny. We obtained germline transmission of the mutant alleles with several targeted cell lines for each construct.
identification of correctly targeted embryonic stem cell clones. We confirmed homologous integration with two PCR reactions on genomic DNA from each embryonic stem cell clone. Integration from the long arm was confirmed by PCR amplification of a 7-kb product with Clontech′s Advantage 2 Polymerase Mix (35 cycles, 68 °C annealing, 8 min extension at 68 °C) with primers SD77for (anneals 5′ to e37a, outside of the targeting construct sequence) and SD64rev (anneals to the 5′ end of the Neo R insert). Homologous integration from the short arm was confirmed by PCR amplification of a 3.5-kb product using Taq polymerase (35 cycles, 60 °C annealing, 4 min extension at 72 °C; New England Biolabs) and primers SD47for (anneals to the 3′ end of the Neo R insert) and SD79rev (anneals 3′ to e37b, outside of the targeting construct sequence). We also confirmed correct targeting by sequencing through the substituted region of the Cacna1b gene of Cacna1b aa*/aa and Cacna1b b*b/b*b mice.
We used BsrGI to identify the exon present in the normal e37a position. In BsrGI digests of PCR products amplified using primers SD62for (anneals upstream of the normal e37a position) and SD64rev (35 cycles, 60 °C annealing, 2 min extension at 72 °C with Taq polymerase), e37a was digested by BsrGI (617 and 1,156 bp), whereas e37b* was not (uncut, 1,773 bp). Similarly, we used XhoI to identify the exon present in the normal e37b position, digesting PCR products amplified using primers SD47for and SD48rev (anneals downstream of the normal e37b position). E37b has two XhoI sites (generating products of 144, 216 and 636 bp), and e37a* has one XhoI site (generating products of 144 and 852 bp).
Neo r cassette deletion. We genotyped F1 animals with genomic DNA from tails, using the four primer sets described above. We crossed more than eight positive animals identified for each of the two mutations with a Cre deletor strain (B6.FVB-Tg(EIIa-cre)C5379Lmgd/J; Jackson Laboratory stock no. 003724) to delete the Neo R gene. We genotyped ΔNeo R mice for appropriate e37 mutations (see genotyping below). We crossed ΔNeo R siblings carrying appropriate mutations to produce homozygotes that were maintained by crossing of sibling homozygotes. We maintained at least two separate homozygous lines for each mutation.
anti-rabbit IgG (Invitrogen) for Ca V 2.2 at room temperature for 2 h. To colabel CGRP and IB4, 1:100 Cy5-conjugated goat anti-guinea pig IgG (Abcam) and 1:100 FITC-conjugated IB4 (Invitrogen) were applied together for 2 h at room temperature. After washing, sections were mounted with Vectashield (Vector labs). Three separate specificity controls were performed. We incubated sections with antigenic peptide preabsorbed with primary antibody, we omitted the primary antibody and we tested Ca V 2.2 antibodies on tsA201 cells transfected with Ca V 2.1 or mock transfected; we did not observed staining under any of the listed conditions. Polyclonal antibodies to Ca V 2.1 and Ca V 2.2 were from Alomone labs, and we carried out the following controls to test their specificity. (i) Because Ca V 2.1 and Ca V 2.2 are relatively similar, we used clones expressed in tsA201 cells to show that anti-Ca V 2.1 did not cross-react with Ca V 2.2, and likewise that anti-Ca V 2.2 did not cross react with Ca V 2.2. In addition, we observed no signals in transfections lacking Ca V 2.1 and Ca V 2.2, either from western blotting or immunofluorescence. (ii) All signals were lost when we omitted the primary antibody and tested with the secondary antibody alone. (iii) Immunofluorescence signals were lost completely in sections in which we first preabsorbed with Ca V 2.2 antigenic peptide ( Fig. 6) . Details of the immunofluorescence signals are provided in Supplementary methods. behavioral analyses. We tested paw-withdrawal thresholds with Plantar Testing Instruments (IITC) 27 on 8-to 16-week-old male mice. We applied a high-intensity beam (set at 20%, ~45 W) to the middle of the plantar surface of a resting mouse. Paw-withdrawal latency was measured to the nearest 0.1 s, with a cutoff value of 20 s. We injected 3 μg morphine sulfate in a volume of 5 μl intrathecally under anesthesia (2% isoflurane, vol/vol) with a 28-gauge needle connected to a microsyringe through a PE 50 polyester catheter (15 cm) 28 . We tested paw-withdrawal thresholds before and 10, 20, 30, 40, 50 and 60 min after morphine injection. We calculated the percentage of maximum possible effect of morphine (%MPE) using the following formula: %MPE = (PWL morphine -PWL baseline )100/(20 -PWL baseline ), where PWL is paw-withdrawal latency. We used the area under the curve of %MPE to compare the overall effect of intrathecal morphine among the three genotypes. Data shown in figures are means ± s.e.m. of measurements from at least ten animals for each genotype.
Statistical analysis. Data are presented as means ± s.e.m. Comparisons of mean differences between groups were made by unpaired two-tailed Student's t-test unless otherwise stated. P < 0.05 was considered to be statistically significant. We used the software Origin 6.1.
